Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 12% survival rate, highlighting the need for novel therapies. c-MYC overexpression, driven by upstream mutations and amplifications, reprograms tumor metabolism and promotes proliferation, migration and metastasis. This study...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ana García García, María Ferrer Aporta, Germán Vallejo Palma, Antonio Giráldez Trujillo, Raquel Castillo-González, David Calzón Lozano, Alberto Mora Perdiguero, Raúl Muñoz Velasco, Miguel Colina Castro, Elena de Simone Benito, Raúl Torres-Ruiz, Sandra Rodriguez-Perales, Jonas Dehairs, Johannes V. Swinnen, Juan Carlos Garcia-Cañaveras, Agustín Lahoz, Sandra Montalvo Quirós, Carlos del Pozo-Rojas, Clara Luque Rioja, Francisco Monroy, Diego Herráez-Aguilar, Marina Alonso Riaño, José Luis Rodríguez Peralto, Víctor Javier Sánchez-Arévalo Lobo
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2025-02-01
Saila:	Nature Communications
Sarrera elektronikoa:	https://doi.org/10.1038/s41467-025-56894-8
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!